Gooch & Housego (GHH) AGM 2025 presentation summary
Event summary combining transcript, slides, and related documents.
AGM 2025 presentation summary
11 Mar, 2026Business overview and performance
2024 revenue reached £136M, with sector split: Life Sciences 25%, Aerospace & Defence 25%, Industrial & Telecom 50%.
Customers demand specialized, high-performance photonics solutions, driving innovation.
Revenue by region: America 42%, Europe 40%, Rest of World 18%.
Employs 980 staff across 10 global manufacturing and design sites.
Strategic direction and operational progress
Strategy centers on innovation, customer focus, and sustainable growth through four priorities: people, self-help, technology, and investment.
R&D investment increased to £7.8M (5.8% of sales) in FY2024; new product revenue rose to £25.3M.
On-time delivery improved to 83.9%, and customer NPS climbed to 42.
Outsourcing revenue grew to 8.5% of group total, with plans to exceed 25%.
Acquisitions and value creation
Acquired Phoenix Optical in October 2024 for up to £6.75M, enhancing precision optics capabilities.
Acquisition brings revenue and cost synergies, strengthens A&D relationships, and adds scalable sovereign capability.
Technology focus areas include medical lasers, semiconductor AO, submarine networks, and bio-photonics.
Over £50M margin-accretive business expected from new products in these areas.
Latest events from Gooch & Housego
- Revenue up, profit down; strong order book and A&D/Life Sciences offset industrial weakness.GHH
H2 202411 Mar 2026 - Revenue and profit fell, but improved margins and a strong order book support a positive outlook.GHH
H1 202411 Mar 2026 - Acquisition creates a U.S. optical systems hub, boosting defense capabilities and growth potential.GHH
M&A announcement11 Mar 2026 - Revenue and profit surged, led by A&D and Life Sciences, with strong order cover for FY2025.GHH
H1 202511 Mar 2026 - Double-digit revenue and profit growth driven by A&D and acquisitions, with a record order book.GHH
H2 202511 Mar 2026 - Solid FY2024 results and acquisitions set the stage for growth in Life Sciences and Defence.GHH
Investor presentation11 Mar 2026 - Double-digit revenue growth and record order intake driven by A&D and new technology focus.GHH
AGM 2026 presentation11 Mar 2026 - Revenue delays impact FY2024, but strategic progress and FY2025 outlook remain strong.GHH
Trading update11 Mar 2026 - Strong second half trading and robust cash generation position the group for next year's recovery.GHH
Trading update11 Mar 2026